- Healey ALS Platform Trial fully enrolled; top-line data expected 2H 2022
- Significant survival benefit from RESCUE-ALS open label extension (OLE) Phase 2 trial to be presented at upcoming Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Nashville, TN March 13-16, 2022
- VISIONARY-MS to conclude early due to COVID pandemic-related challenges. Unblinded data expected 2H 2022; insights to inform new Phase 2/3 MS trial.
- REPAIR-MS Phase 2 Trial initiates second cohort to confirm target engagement in non-active progressive MS
- COVID-19 Phase 2 trial completes enrollment; top-line results expected mid-year 2022
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
All news is property of their respective owners.
